« Back
Home /
ZLD1039

ZLD1039

Item no.	DCC-DC26039-100mg
Manufacturer	DCChemicals
CASRN	1826865-46-6
Amount	100 mg
Quantity options	100 mg 1 g 250 mg
Category	Reagents & Chemicals Molecules
Type	Chemicals
Specific against	other
Purity	>98%
Smiles	O1C([H])([H])C([H])([H])C([H])(C([H])([H])C1([H])[H])N(C([H])([H])C([H])([H])[H])C1=C([H])C(C2=C([H])N=C(C([H])=C2[H])N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])=C([H])C(C(N([H])C([H])([H])C2C(N([H])C(C([H])([H])[H])=C3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3=2)=O)=O)=C1C([H])([H])[H]
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	3-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,5,6,7,8-hexahydro-1-methyl-3-oxo-4-isoquinolinyl)methyl]-2-methyl-5-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-benzamide
Similar products	1826865-46-6
Available
Manufacturer - Applications	ZLD1039 is a novel, orally active EZH2 inhibitor demonstrating high selectivity and potency. It effectively suppresses PRC2 enzymatic activity across wild-type EZH2 (IC50 = 5.6 nM) and mutant forms (Y641F: 15 nM; A677G: 4.0 nM), while exhibiting significant anti-tumor and anti-metastatic effects in breast cancer models.
Molecular Weight	612, 8047

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Delivery expected until 10/2/2025

Express Delivery: Save 3 days

Compare

Add to wishlist

Get an offer